Please login to the form below

Not currently logged in
Email:
Password:

eye disease

This page shows the latest eye disease news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: DeepMind and NHS success in AI eyecare, Bayer invests in COPD, Alecensa OK in Scotland

Daily Brief: DeepMind and NHS success in AI eyecare, Bayer invests in COPD, Alecensa OK in Scotland

The latest from pharma, biotech and healthcare. DeepMind and NHS hospital’s AI shows great promise in eye diseases. ... Google’s DeepMind unveiled early results from its AI-based research partnership with London’s  Moorfields Eye Hospital yesterday

Latest news

  • Spark sputters on haemophilia A gene therapy safety scare Spark sputters on haemophilia A gene therapy safety scare

    trials, including studies of its own approved eye disease therapy Luxturna. ... haemophilia will within a few short years be a reality for people with this disease, ”asserted Marrazzo on the call.

  • UK firm Nightstar bags FDA fast-track status for gene therapy UK firm Nightstar bags FDA fast-track status for gene therapy

    A gene therapy for an inherited eye disease developed by Nightstar Therapeutics has picked up a coveted designation from the FDA that could accelerate its development. ... of the therapy into one eye and compared to a group with no treatment.

  • Novartis buys gene therapy firm AveXis for $8.7bn Novartis buys gene therapy firm AveXis for $8.7bn

    ex-US rights to Spark Therapeutics’recently-approved Luxturna (voretigene neparvovec-rzyl) for an inherited eye disease. ... Last year, Biogen secured approval for the first drug treatment for SMA, a progressive, debilitating muscle-wasting disease

  • NICE backs GSK’s €594k gene therapy for rare disease NICE backs GSK’s €594k gene therapy for rare disease

    Children with the rare disease have compromised immune systems and are extremely vulnerable to infections, and usually are kept in isolation. ... The new guidance comes in the same week that Spark Therapeutics announced its pricing for RPE65-mediated eye

  • Shire files dry eye drug lifitegrast in Europe Shire files dry eye drug lifitegrast in Europe

    Shire is awaiting the go-ahead of lifitegrast in the EU, seeking approval for the would-be dry eye disease blockbuster. ... Dry eye disease causes discomfort, stinging and blurry vision, and can significantly affect quality of life in some patients,

More from news
Approximately 6 fully matching, plus 49 partially matching documents found.

Latest Intelligence

  • Pharma deals during March 2013 Pharma deals during March 2013

    However, ophthalmology is increasingly an area of interest in the industry with potential for growth as the global population ages; it is estimated that around 25m people have dry eye disease ... 175. SARcode Bioscience/ Shire. Acquisition. SAR 1118 for

  • Interview: Joseph Jimenez, Novartis Interview: Joseph Jimenez, Novartis

    There is a growing demand for eye care, owing to the rising prevalence of eye disease, an ageing global population and increased demand for healthcare in emerging markets. ... This is demonstrated by the fact that rare disease research is central to its

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • The power of observation in gathering patient insights

    For example, we recently conducted a multi-country research project for a rare eye disease. ... Patients walked us around their homes; sharing with us stories about life before and after their disease, adding significant layers of insight to the findings

  • PAN trio run for charity

    RP is an inherited disease of the eye, where the light sensitive cells of the retina cease to function and die away. ... However, the research being undertaken at Moorfields Eye Hospital hopes to slow or even reverse this disease by injecting cells from

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics